CN114836424B - lncRNA IFFD及其在猪卵巢颗粒细胞中的应用 - Google Patents

lncRNA IFFD及其在猪卵巢颗粒细胞中的应用 Download PDF

Info

Publication number
CN114836424B
CN114836424B CN202210605258.9A CN202210605258A CN114836424B CN 114836424 B CN114836424 B CN 114836424B CN 202210605258 A CN202210605258 A CN 202210605258A CN 114836424 B CN114836424 B CN 114836424B
Authority
CN
China
Prior art keywords
iffd
lncrna
granulosa cells
artificial sequence
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210605258.9A
Other languages
English (en)
Other versions
CN114836424A (zh
Inventor
周小枫
袁晓龙
张哲�
李加琪
何颖婷
潘向春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China Agricultural University
Original Assignee
South China Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China Agricultural University filed Critical South China Agricultural University
Priority to CN202210605258.9A priority Critical patent/CN114836424B/zh
Publication of CN114836424A publication Critical patent/CN114836424A/zh
Application granted granted Critical
Publication of CN114836424B publication Critical patent/CN114836424B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0681Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

本发明公开一种lncRNA IFFD及其在猪卵巢颗粒细胞中的应用,属于细胞工程和基因工程技术领域。本发明以lncRNA IFFD为研究对象,通过构建lncRNA IFFD超表达载体和合成siRNA,分别将lncRNA IFFD超表达载体或siRNA转染到卵巢颗粒细胞,然后检测与卵巢颗粒细胞凋亡、增殖以及E2分泌相关的信号通路基因mRNA以及蛋白水平的变化,最后再检测卵巢颗粒细胞的表型变化。结果表明,lncRNA IFFD可促进卵巢颗粒细胞的凋亡和抑制增殖以及E2分泌。本发明通过探究lncRNA IFFD对卵巢颗粒细胞的影响,为研究卵巢卵泡闭锁以及初情启动障碍等机制具有很好的应用价值。

Description

lncRNA IFFD及其在猪卵巢颗粒细胞中的应用
技术领域
本发明属于细胞工程和基因工程技术领域,特别涉及一种lncRNA IFFD及其在猪卵巢颗粒细胞中的应用。
背景技术
卵泡发育是一个多细胞共同参与,包含卵母细胞成熟、颗粒细胞(Granulosacells,GCs)增殖、凋亡及类固醇激素分泌等复杂的生物学过程,这些过程大都涉及到与表观遗传调控相关的染色质结构的改变以及基因的转录调控等。颗粒细胞死亡的增加很可能是直接或间接阻碍卵泡发育的细胞机制。越来越多的报道表明lncRNAs和miRNAs在卵泡发育过程中发挥着至关重要的作用。过表达 lncRNA-let可通过上调TIMP2表达,抑制GCs迁移,促进凋亡。LncRNA Gm2044 作为miR-138-5p海绵促进小鼠腔前卵泡GCs中E2的合成。
发明内容
为了克服现有技术的缺点与不足,本发明的首要目的在于提供一种lncRNA IFFD。
本发明的另一目的在于提供上述lncRNA IFFD在猪卵巢颗粒细胞中的应用。
本发明的再一目的在于提供抑制lncRNA IFFD表达的小干扰RNA片段 (siRNA)。
在本发明中,我们发现一种新的lncRNA,根据其功能命名为卵泡发育抑制因子(inhibitory factor of follicular development,IFFD)。LncRNA IFFD位于猪第 1号染色体,全长395bp。
本发明的目的通过下述技术方案实现:
本发明提供一种lncRNA IFFD,其核苷酸序列如SEQ ID NO:1所示。
上述lncRNA IFFD相关的生物材料,为下述生物材料中的任意一种或多种组合;
1)编码所述lncRNA IFFD的DNA分子;
2)含有1)中所述DNA分子的表达盒;
3)含有1)中所述DNA分子的重组载体,或含有2)中所述表达盒的重组载体;
4)抑制所述lncRNA IFFD表达的小干扰RNA片段(siRNA);
5)含有1)中所述DNA分子的重组细胞,或含有2)中所述表达盒的重组细胞,或含有3)所述重组载体的重组细胞,或转染有4)中所述小干扰RNA 片段的重组细胞。
进一步的,1)中所述DNA分子可通过如下方式制备得到:提取猪卵巢颗粒细胞的RNA,将其逆转录成cDNA,以cDNA为模板进行PCR扩增,得到 DNA分子。
更进一步的,PCR扩增所用引物如下所示:
lncRNA IFFD Forward:
lncRNA IFFD Reverse:
进一步的,3)中所述重组载体可通过如下方式制备得到:将所述DNA分子插入至pcDNA3.1载体的Hind III和Kpn I酶切位点之间,得到重组载体;
所述DNA分子的序列如SEQ ID NO:2所示。
进一步的,4)中所述小干扰RNA片段如下所示:
si-lnc IFFD-1:5′-GCUCUAGCAGCUCGGACAA-3′;
上述lncRNA IFFD或上述lncRNA IFFD相关的生物材料在猪卵巢颗粒细胞中的应用。
体外环境下,lncRNA IFFD能抑制猪卵巢颗粒细胞的增殖,和/或促进猪卵巢颗粒细胞的凋亡。
进一步,上述lncRNA IFFD或上述lncRNA IFFD相关的生物材料在制备调控猪卵巢颗粒细胞增殖和/或凋亡的药物中的应用。
所述的调控猪卵巢颗粒细胞的增殖和/或凋亡通过如下方式实现:
增加lncRNA IFFD抑制猪卵巢颗粒细胞的增殖,促进猪卵巢颗粒细胞的凋亡;或减少lncRNA IFFD促进猪卵巢颗粒细胞的增殖,抑制猪卵巢颗粒细胞的凋亡;
更进一步的,具体为下述应用中的任意一种或多种组合:
a)增加lncRNA IFFD,抑制猪卵巢颗粒细胞的增殖;
b)增加lncRNA IFFD,促进猪卵巢颗粒细胞的凋亡;
c)减少lncRNA IFFD,促进猪卵巢颗粒细胞的增殖;
d)减少lncRNA IFFD,抑制猪卵巢颗粒细胞的凋亡。
上述lncRNA IFFD或上述lncRNA IFFD相关的生物材料在调控猪卵巢颗粒细胞中E2(雌二醇)生成的应用。
所述的调控猪卵巢颗粒细胞中E2(雌二醇)生成通过如下方式实现:
增加lncRNA IFFD抑制E2的生成;和/或减少lncRNA IFFD促进E2的生成。
所述的增加lncRNA IFFD为通过增加外源性lncRNA IFFD的方式实现;
所述的减少lncRNA IFFD为抑制lncRNA IFFD表达的siRNA转染到猪卵巢颗粒细胞的方式实现。
所述的增加外源性lncRNA IFFD通过如下方法实现:将lncRNA IFFD连接到pcDNA3.1载体上,构建含有lncRNA IFFD的超表达载体;然后将含有lncRNA IFFD的超表达载体转染到猪卵巢颗粒细胞中。
本发明提供抑制lncRNA IFFD表达的siRNA,序列如下:
si-lnc IFFD-1:5′-GCUCUAGCAGCUCGGACAA-3′。
本发明的验证结果如下:
1、合成2对干扰lncRNA IFFD的小片段/对照(si-lnc IFFD/siRNA-NC),筛选并检测其干扰效率。结果可知,将基因干扰小片段转染到卵巢颗粒细胞中,通过qRT-PCR手段,最终筛选干扰效果较好的si-lnc IFFD-1小片段进行后续实验。
si-lnc IFFD-1:5′-GCUCUAGCAGCUCGGACAA-3′;
2、我们分别将pcDNA3.1-lnc IFFD或si-lnc IFFD(si-lnc IFFD-1)转染到卵巢颗粒细胞,利用qRT-PCR、WB和Edu法分别检测lncRNA IFFD对颗粒细胞增殖相关基因表达和增殖的影响。qRT-PCR和WB结果显示,pcDNA3.1-lnc IFFD 抑制细胞周期相关基因(PCNA、CDK2、CDK4、CCNB1和CCND1)的表达水平。EdU染色显示,pcDNA3.1-lnc IFFD组的细胞增殖率显著低于pcDNA3.1组。同时,si-lnc IFFD促进PCNA、CCNB1和CCND1的表达水平。si-lncIFFD组的细胞增殖率显著高于siRNA-NC组。综上,lncRNA IFFD能抑制猪卵巢颗粒细胞的增殖。
3、我们分别将pcDNA3.1-lnc IFFD或si-lnc IFFD(si-lnc IFFD-1)转染到卵巢颗粒细胞,利用qRT-PCR、WB和Annexin V-FITC法分别检测lncRNA IFFD 对颗粒细胞凋亡相关基因表达和凋亡的影响。qRT-PCR和WB结果显示, pcDNA3.1-lnc IFFD促进细胞促凋亡相关基因(Caspase3、Caspase9和BAX)的表达水平。流式细胞仪分析结果显示,pcDNA3.1-lncIFFD组的细胞凋亡率(早期凋亡+晚期凋亡)显著高于pcDNA3.1组。同时,si-lnc IFFD抑制Caspase3、 BAX和BCL2的表达水平。si-lnc IFFD组的细胞凋亡率显著低于siRNA-NC组。综上,lncRNA IFFD能促进猪卵巢颗粒细胞的凋亡。
4、我们分别将pcDNA3.1-lnc IFFD或si-lnc IFFD(si-lnc IFFD-1)转染到卵巢颗粒细胞,利用qRT-PCR、WB和ELISA法分别检测lncRNA IFFD对颗粒细胞E2分泌相关基因表达和E2分泌的影响。qRT-PCR和WB结果显示, pcDNA3.1-lnc IFFD抑制细胞E2分泌相关基因(CYP19A1和CYP11A1)的表达水平。ELISA结果显示,pcDNA3.1-lnc IFFD组的E2浓度显著低于pcDNA3.1 组。同时,si-lnc IFFD促进CYP19A1、CYP11A1和HSD17B1的表达水平。si-lncIFFD组的E2浓度显著高于siRNA-NC组。综上,lncRNA IFFD能抑制猪卵巢颗粒细胞E2的分泌。
本发明相对于现有技术具有如下的优点及效果:
(1)lncRNA IFFD可能直接或间接参与了卵泡闭锁、卵泡发育以及初情启动,本发明是以lncRNA IFFD(见SEQ ID NO:1)为研究对象,采用了分子和细胞生物学方法研究其在猪卵巢颗粒细胞中的应用:lncRNA IFFD可促进卵巢颗粒细胞的凋亡和抑制增殖以及E2分泌。对研究卵巢卵泡闭锁以及初情启动障碍等具有很好的应用价值。
(2)本发明技术方案设计周详,结果可靠。为证实lncRNA IFFD对卵巢颗粒细胞增殖、凋亡以及E2分泌的影响,本发明从多层次、多角度验证,在相关信号通路基因、mRNA以及蛋白水平验证,最后在卵巢颗粒细胞的表型上验证。
附图说明
图1是qRT-PCR检测lncRNA IFFD的超表达和干扰效率;其中,A为pcDNA3.1-lncIFFD的超表达效率图,B为si-lnc IFFD干扰效率图。
图2是lncRNA IFFD对颗粒细胞增殖的影响图;其中,A为超表达和干扰 lncRNAIFFD对颗粒细胞增殖相关基因的mRNA表达水平的影响;B为超表达和干扰lncRNA IFFD对颗粒细胞增殖相关基因的蛋白表达水平的影响;C超表达和干扰lncRNA IFFD对颗粒细胞增殖率的影响。
图3是lncRNA IFFD对颗粒细胞凋亡的影响图;其中,A为超表达和干扰 lncRNAIFFD对颗粒细胞凋亡相关基因的mRNA表达水平的影响;B为超表达和干扰lncRNA IFFD对颗粒细胞凋亡相关基因的蛋白表达水平的影响;C为超表达和干扰lncRNA IFFD对颗粒细胞凋亡率的影响。
图4是lncRNA IFFD对颗粒细胞E2分泌的影响图;其中,A为超表达和干扰lncRNAIFFD对颗粒细胞E2分泌相关基因的mRNA表达水平的影响;B为超表达和干扰lncRNA IFFD对颗粒细胞E2分泌相关基因的蛋白表达水平的影响;C为超表达和干扰lncRNA IFFD对颗粒细胞E2分泌的影响。
具体实施方式
下面结合实施例对本发明作进一步详细的描述,但本发明的实施方式不限于此。下列实施例中未注明具体条件的实验方法,通常按照常规条件。
本发明中应用统计学方法,分析各实施例中3次独立实验的结果,分别计算“平均值±标准差”,使用单因素方差分析进行差异显著性分析(图中“*”表示P<0.05,“**”表示P<0.01)。
实施例1构建lncRNA IFFD的超表达载体
(1)通过5′和3′RACE,以抽提的猪颗粒细胞的cDNA为模板扩增lncRNA IFFD;扩增的片段经纯化回收、连接pMD18T载体(购自Takara公司)、转化、筛选、测序鉴定正确后抽提普通质粒。
(2)BioEdit软件分析发现lncRNA IFFD全长序列无Hind III和Kpn I两种限制性内切酶酶切位点,而pcDNA3.1载体存在Hind III和Kpn I酶切位点。其上下游引物分别加上Hind III和Kpn I酶切位点序列。以lncRNA IFFD重组 pMD18T普通质粒为模板,PCR扩增;片段经纯化回收、双酶切、连接pcDNA3.1 载体、转化、筛选、测序鉴定正确后抽提无内毒素质粒(无内毒素质粒小量提取试剂盒购自美国Magen公司),命名为pcDNA3.1-lnc IFFD。
本发明所用到的lncRNA IFFD引物:
lncRNA IFFD Forward:
lncRNA IFFD Reverse:
注:黑色加粗字体部分为保护碱基,下划线为酶切位点。
实施例2卵巢颗粒细胞的培养和转染
(1)采集健康母猪的新鲜卵巢,置于含1%双抗的PBS缓冲液中(冰上),快速运回实验室处理;
(2)先在细胞房外用含2%双抗的PBS清洗卵巢3~5次,置于烧杯中,放入传递窗;
(3)酒精擦拭细胞房超净台,镊子夹取卵巢,用注射器吸取卵泡液,打入含有5mLDMEM培养液的离心管中,每管抽取卵泡液至9mL;
(4)1000rpm离心5min,弃上清,加入5mL PBS,吹打混匀,清洗两次;
(5)配制完全培养基:89%DMEM、10%血清和1%双抗,上下颠倒混匀;
(6)加5mL完全培养基重悬细胞沉淀;
(7)75mL培养瓶中先加入10mL完全培养基,再加入上述重悬液;
(8)显微镜观察后置于37℃,5%CO2培养箱中培养,24h后观察颗粒细胞生长情况,等颗粒细胞长至90%左右,倒掉培养基,用预热的含1%双抗的 PBS洗3遍;
(9)加入胰蛋白酶消化,放入培养箱3min左右,显微镜下观察至大部分细胞漂起,立即加入等量终止液终止消化;
(10)DMEM清洗2遍,期间1000rpm离心5min;
(11)用完全培养基轻轻重悬细胞沉淀,均匀分到每个孔中,用完全培养基补充体积,轻轻摇匀,放培养箱中培养;
(12)24h左右,观察细胞状态,待细胞汇合度达80%左右时准备转染;
(13)转染方法按Invitrogen公司的3000试剂盒说明书进行,每组设置3个重复;
(14)转染后的孔板置于37℃,5%CO2培养箱中培养,转染后24h~72h,观察细胞状态,生长良好即可收集细胞。
所述的双抗为青霉素和链霉素。
实施例3qRT-PCR
本发明中基因的qRT-PCR检测采用Maxima SYBR Green qPCR Master Mix (2X)试剂盒(Thermo Scientific公司)。实验采用比较Ct值法检测样品基因的含量,具体计算公式如下:
基因相对表达量=2-{〈﹙实验组目的基因Ct值﹚-﹙实验组内参基因Ct值﹚〉 -〈﹙对照组目的基因Ct值﹚-﹙对照组内参基因Ct值﹚〉}
检测基因用GAPDH做内参,本发明所用到的qRT-PCR引物为:
qRT-PCR-IFFD Forward:5′-GTCGGGCGATGCTATCAGAG-3′;
Reverse:5′-GGCCTTGCTAAGCCATACCT-3′;
qRT-PCR-Caspase3 Forward:5′-ACATGGAAGCAAATCAATGGAC-3′;
Reverse:5′-TGCAGCATCCACATCTGTACC-3′;
qRT-PCR-Caspase8 Forward:5′-GAGCCTGGACTACATCCCAC-3′;
Reverse:5′-GTCCTTCAATTCCGACCTGG-3′;
qRT-PCR-Caspase9 Forward:5′-GCTGAACCGTGAGCTTTTCA-3′;
Reverse:5′-CCTGGCCTGTGTCCTCTAAG-3′;
qRT-PCR-BAX Forward:5′-ACTTCCTTCGAGATCGGCTG-3′;
Reverse:5′-AAAGACACAGTCCAAGGCGG-3′;
qRT-PCR-BCL2 Forward:5′-GATGCCTTTGTGGAGCTGTATG-3′;
Reverse:5′-CCCGTGGACTTCACTTATGG-3′;
qRT-PCR-PCNA Forward:5′-TCGTTGTGATTCCACCACCAT-3′;
Reverse:5′-TGTCTTCATTGCCAGCACATTT-3′;
qRT-PCR-CDK1 Forward:5′-AGGTCAAGTGGTAGCCATGAA-3′;
Reverse:5′-TCCATGAACTGACCAGGAGG-3′;
qRT-PCR-CDK2 Forward:5′-AAAAGATCGGAGAGGGCACG-3′;
Reverse:5′-GCAGTACTGGGTACACCCTC-3′;
qRT-PCR-CDK4 Forward:5′-CCTCCCGGTATGAACCAGTG-3′;
Reverse:5′-TGCTCAAACACCAGGGTCAC-3′;
qRT-PCR-CCNA1 Forward:5′-GCGCCAAGGCTGGAATCTAT-3′;
Reverse:5′-CCTCAGTCTCCACAGGCTAC-3′;
qRT-PCR-CCNA2 Forward:5′-GTACTGAAGGCCGGGAACTC-3′;
Reverse:5′-AGCTGGCCTCTTTTGAGTCT-3′;
qRT-PCR-CCNB1 Forward:5′-ACGGCTGTTAGCTAGTGGTG-3′;
Reverse:5′-GAGCAGTTCTTGGCCTCAGT-3′;
qRT-PCR-CCNB2 Forward:5′-TGGAAATCGAGTTACAACCAGA-3′;
Reverse:5′-TGGAGCCAACATTTCCATCTGT-3′; qRT-PCR-CCND1 Forward:5′-CTTCCATGCGGAAGATCGTG-3′;
Reverse:5′-TGGAGTTGTCGGTGTAGATGC-3′;
qRT-PCR-CCND2 Forward:5′-TTCCCCAGTGCTCCTACTTC-3′;
Reverse:5′-CACAACTTCTCAGCCGTCAG-3′;
qRT-PCR-CCNE1 Forward:5′-AGCCTGTGAAAACCCCTGTT-3′;
Reverse:5′-TCCAGAAGAATCGCTCGCAT-3′;
qRT-PCR-CCNE2 Forward:5′-GGGGGATCAGTCCTTGCATT-3′;
Reverse:5′-AGCCAAACATCCTGTGAGCA-3′;
qRT-PCR-CYP19A1 Forward:5′-CTGAAGTTGTGCCTTTTGCCA-3′;
Reverse:5′-CTGAGGTAGGAAATTAGGGGC-3′;
qRT-PCR-CYP11A1 Forward:5′-TCCCCTCTCCTGGTGACAAT-3′;
Reverse:5′-GCCACATCTTCAGGGTCGAT-3′;
qRT-PCR-STAR Forward:5′-CGACGTTTAAGCTGTGTGCT-3′;
Reverse:5′-ATCCATGACCCTGAGGTTGGA-3′;
qRT-PCR-HSD17B1 Forward:5′-GTCTGGCATCTGACCCATCTC-3′;
Reverse:5′-CGGGCATCCGCTATTGAATC-3′;
qRT-PCR-HSD3B1 Forward:5′-ATCTGCAGGAGATCCGGGTA-3′;
Reverse:5′-CCTTCATGACGGTCTCTCGC-3′;
qRT-PCR-GAPDH Forward:5′-TCACCAGGGCTGCTTTTAACT-3′;
Reverse:5′-CTTGACTGTGCCGTGGAACT-3′;
细胞的总RNA提取参照Takara公司TRIzol操作说明书,具体步骤如下:
(1)颗粒细胞直接加入TRIzol;
(2)室温下放置10min以充分裂解细胞,12000g离心5min,弃沉淀吸上清于新RNase-free管中;
(3)加入0.2mL氯仿(每1mL TRIzol)剧烈震荡15~30s,室温下放置5min后4℃12000g离心15min;
(4)吸取上层水相置于新RNase-free EP管中;
(5)加入0.5mL异丙醇(每1mL TRIzol),轻轻地上下颠倒混匀后在室温放置10min,4℃12000g离心10min;
(6)弃上清后置于室温,沿管壁加入1mL 75%乙醇-DEPC(每1mL TRIzol) 以洗涤RNA,4℃12000g离心5min后尽量弃上清;
(7)真空干燥5~10min,注意避免RNA沉淀干燥过度;
(8)加入DEPC水以溶解RNA沉淀。
使用TaKaRa公司的PrimeScriptTM RT Master Mix(Perfect Real Time)cDNA 反转录试剂盒反转录总RNA。
实施例4Western Blot
(1)单层贴壁细胞(实施例2中的卵巢颗粒细胞)总蛋白的提取与定量:倒掉细胞培养液,加入适量预冷的PBS洗细胞三次以洗去培养液。6孔板细胞每孔加入100~200μL蛋白裂解液和10μL 100mM的PMSF,裂解细胞30min。收集细胞裂解液移至1.5mL离心管中,4℃14000rpm离心5min。利用BCA法测定蛋白样品浓度。
(2)SDS-PAGE电泳:每组取20μg总蛋白和5×上样缓冲液按5:1混合,煮沸5min。SDS-PAGE电泳至溴酚蓝刚出胶底部为止;
(3)转膜:PVDF膜甲醇预处理3~5s,放至转印液浸润30min。取出凝胶,将其放至滤纸上,形成凝胶转印堆积层“三明治”结构。此操作必须将气泡完全去除。100V恒压60~120min;
(4)免疫印记:取出杂交膜,TBST漂洗5min,重复三次。5%脱脂奶粉溶液室温封闭90min,TBST漂洗5min,重复三次。膜用以下稀释的一抗在4℃孵育过夜:PCNA(10205-2-AP,proteintech,1:2000),CCND1(26939-1-AP, proteintech,1:1000),Caspase3(19677-1-AP,proteintech,1:1000),BAX(50599-2-Ig, proteintech,1:5000),CYP19A1(bs-0114R,bioss,1:1000),CYP11A1(13363-1-AP, proteintech,1:1000)和Tubulin(11224-1-AP,proteintech,1:5000)。将膜用TBST 清洗3次后,再用山羊抗兔(ab205718,Abcam,1:10000)或山羊抗鼠(ab6789, Abcam,1:5000)的二抗在室温下孵育2h。ECL发光液处理后,利用Odyssey Fc 图像系统对蛋白条带进行可视化,最后采用ImageJ软件分析蛋白条带。
实施例5颗粒细胞凋亡检测
本发明中Annexin V-FITC技术检测细胞凋亡,参照BioVision公司Annexin V-FITC Apoptosis Detection Kit操作说明书,具体操作步骤如下:
(1)将细胞培养板放置在室温,用2mL PBS溶液轻轻润洗培养板内细胞,去除PBS溶液;
(2)加入不含EDTA的胰酶消化细胞,将细胞轻轻重悬于步骤(1)中的培养基使其密度大约为1×106细胞/mL;
(3)将0.5mL细胞悬液从细胞培养板中(约5×105个细胞)转移到一个干净的离心管内,加入500μL 1×Binding Buffer;
(4)加5μL Annexin V-FITC和室温5μL propidium iodide;
(5)室温避光反应5min;
(6)立即用FACSCalibur流式细胞仪检测分析(每组三个重复)。
实施例6颗粒细胞增殖检测
本发明用EdU法检测细胞增殖,参照锐博公司Cell-LightTM EdU Apollo 567 Invitro Kit检测试剂盒,具体操作步骤如下:
(1)制备50μM EdU培养基:用细胞培养基以1:1000的比例稀释EdU 溶液;
(2)细胞融合度为50~80%时弃培养液,加入100μL 50μM EdU培养基孵育2h;
(3)固定细胞:弃培养液,每孔加入100μL细胞固定液(4%多聚甲醛的 PBS)室温孵育15~30min;
(4)2mg/mL甘氨酸孵育10min,PBS冲洗2次;
(5)弃上清,加入100μL渗透剂(0.5%(v/v)TritonX-100的PBS)透化细胞,PBS冲洗1次;
(6)EdU检测:加入100μL的染色反应液,避光室温孵育30min, PBS冲洗1次,沉淀细胞,弃上清;
(7)DNA染色:每孔加入100μL DAPI反应液,避光室温孵育30min;
(8)加入100μL渗透剂(0.5%(v/v)TritonX-100的PBS)冲洗3次,洗脱DAPI反应液;
(9)荧光显微镜镜检(每组三个重复)。
实施例7ELISA方法测定猪卵巢颗粒细胞上清样本中E2含量
E2浓度检测,参照江苏晶美生物公司的porcine E2 ELISA试剂盒,具体操作步骤如下:在标准孔中分别加50μL不同浓度的标准品,在样品孔中加50μL 待测样品。然后加入100μL辣根过氧化物酶(HRP),37℃孵育60min。洗净后,底物A、B各加50μL,37℃孵育15min。最后加入终止液,在450nm处测量 OD值。
结果分析:
1、为了研究lncRNA IFFD对卵巢颗粒细胞功能的影响,我们将lncRNA IFFD 超表达载体(pcDNA3.1-lnc IFFD)或小干扰RNA(si-lnc IFFD)转染到卵巢颗粒细胞,来探索lncRNA IFFD对卵巢颗粒细胞增殖、凋亡以及E2分泌的影响;其中,lncRNA IFFD超表达载体的构建方法为:首先通过5′和3′RACE扩增 lncRNA IFFD,测序验证正确后提取普通质粒,再通过普通质粒与pcDNA3.1载体的双酶切、连接、转化、挑单克隆测序验证正确后提取无内毒素质粒。对提取的无内毒素质粒进行双酶切鉴定,验证lncRNA IFFD超表达载体是否构建成功。最后将构建成功的pcDNA3.1-lnc IFFD转染到卵巢颗粒细胞,通过qRT-PCR 以及WB方法验证,如图1A所示,随着pcDNA3.1-lnc IFFD载体浓度增加, lncRNA IFFD的表达水平也升高。
2、合成2对干扰lncRNA IFFD的小片段/对照(si-lnc IFFD/siRNA-NC),筛选并检测其干扰效率。结果如图1B所示,将基因干扰小片段转染到卵巢颗粒细胞中,通过qRT-PCR以及WB手段,最终筛选干扰效果较好的si-lnc IFFD-1片段进行后续实验。
si-lnc IFFD-1:5′-GCUCUAGCAGCUCGGACAA-3′;
si-lnc IFFD-2:5′-GGAGGAGAUCGGGAGCGAAUG-3′;
上述干扰小片段由广州市锐博生物科技有限公司合成;对照siRNA-NC来自广州市锐博生物科技有限公司。
3、我们分别将pcDNA3.1-lnc IFFD或si-lnc IFFD(si-lnc IFFD-1)转染到卵巢颗粒细胞,利用qRT-PCR、WB和Edu法分别检测lncRNA IFFD对颗粒细胞增殖相关基因表达和增殖的影响。qRT-PCR和WB结果如图2A、B显示, pcDNA3.1-lnc IFFD抑制细胞周期相关基因(PCNA、CDK2、CDK4、CCNB1 和CCND1)的表达水平。EdU染色如图2C显示,pcDNA3.1-lnc IFFD组的细胞增殖率显著低于pcDNA3.1组。同时,如图2A、B显示,si-lnc IFFD促进PCNA、 CCNB1和CCND1的表达水平。如图2C显示,si-lnc IFFD组的细胞增殖率显著高于siRNA-NC组。综上,lncRNA IFFD能抑制猪卵巢颗粒细胞的增殖。
4、我们分别将pcDNA3.1-lnc IFFD或si-lnc IFFD(si-lnc IFFD-1)转染到卵巢颗粒细胞,利用qRT-PCR、WB和Annexin V-FITC法分别检测lncRNA IFFD 对颗粒细胞凋亡相关基因表达和凋亡的影响。qRT-PCR和WB结果如图3A、B 显示,pcDNA3.1-lnc IFFD促进细胞促凋亡相关基因(Caspase3、Caspase9和BAX) 的表达水平。流式细胞仪分析结果如图3C显示,pcDNA3.1-lnc IFFD组的细胞凋亡率(早期凋亡+晚期凋亡)显著高于pcDNA3.1组。同时,如图3A、B显示,si-lnc IFFD抑制Caspase3、BAX和BCL2的表达水平。如图3C显示,si-lnc IFFD组的细胞凋亡率显著低于siRNA-NC组。综上,lncRNA IFFD能促进猪卵巢颗粒细胞的凋亡。
5、我们分别将pcDNA3.1-lnc IFFD或si-lnc IFFD(si-lnc IFFD-1)转染到卵巢颗粒细胞,利用qRT-PCR、WB和ELISA法分别检测lncRNA IFFD对颗粒细胞E2分泌相关基因表达和E2分泌的影响。qRT-PCR和WB结果如图4A、B显示,pcDNA3.1-lnc IFFD抑制细胞E2分泌相关基因(CYP19A1和CYP11A1) 的表达水平。ELISA结果如图4C显示,pcDNA3.1-lnc IFFD组的E2浓度显著低于pcDNA3.1组。同时,如图4A、B显示,si-lnc IFFD促进CYP19A1、CYP11A1 和HSD17B1的表达水平。如图4C显示,si-lnc IFFD组的E2浓度显著高于 siRNA-NC组。综上,lncRNA IFFD能抑制猪卵巢颗粒细胞E2的分泌。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
序列表
<110> 华南农业大学
<120> lncRNA IFFD及其在猪卵巢颗粒细胞中的应用
<160> 54
<170> SIPOSequenceListing 1.0
<210> 1
<211> 395
<212> RNA
<213> 人工序列(Artificial Sequence)
<220>
<223> lncRNA IFFD
<400> 1
acccuguaag gggacuggaa aguccagccc aaacgcucuc uugggaaagg aacaaagucc 60
cgguggguua caaccugacc cuaggaguaa aagauguuaa ggccugccau ggaaauuaaa 120
aacuuccguc gggcgaugcu aucagagagg agagaaccaa ggggguccug cugcaucucu 180
ggcucuagca gcucggacaa gaucccgaac auacuucauc acgaaaugag agaggaaaac 240
cagcaggcuu uccagguaug gcuuagcaag gccucguucc cacggcaucc accugggcuc 300
cccgcccaag gguggcaggc ggcccuagca ggaggagauc gggagcgaau gggagagcug 360
gucaggaagg ugguguaggg accaucccca aauac 395
<210> 2
<211> 395
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> 编码lncRNA IFFD的DNA分子
<400> 2
accctgtaag gggactggaa agtccagccc aaacgctctc ttgggaaagg aacaaagtcc 60
cggtgggtta caacctgacc ctaggagtaa aagatgttaa ggcctgccat ggaaattaaa 120
aacttccgtc gggcgatgct atcagagagg agagaaccaa gggggtcctg ctgcatctct 180
ggctctagca gctcggacaa gatcccgaac atacttcatc acgaaatgag agaggaaaac 240
cagcaggctt tccaggtatg gcttagcaag gcctcgttcc cacggcatcc acctgggctc 300
cccgcccaag ggtggcaggc ggccctagca ggaggagatc gggagcgaat gggagagctg 360
gtcaggaagg tggtgtaggg accatcccca aatac 395
<210> 3
<211> 19
<212> RNA
<213> 人工序列(Artificial Sequence)
<220>
<223> si-lncIFFD-1
<400> 3
gcucuagcag cucggacaa 19
<210> 4
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<220>
<223> si-lnc IFFD-2
<400> 4
ggaggagauc gggagcgaau g 21
<210> 5
<211> 29
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> lncRNA IFFD Forward
<400> 5
ccaagctttc tcttgggaaa ggaacaaag 29
<210> 6
<211> 29
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> lncRNA IFFD Reverse
<400> 6
ggggtacctc cctacaccac cttcctgac 29
<210> 7
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-IFFD Forward
<400> 7
gtcgggcgat gctatcagag 20
<210> 8
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-IFFD Reverse
<400> 8
ggccttgcta agccatacct 20
<210> 9
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Caspase3 Forward
<400> 9
acatggaagc aaatcaatgg ac 22
<210> 10
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Caspase3 Reverse
<400> 10
tgcagcatcc acatctgtac c 21
<210> 11
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Caspase8 Forward
<400> 11
gagcctggac tacatcccac 20
<210> 12
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Caspase8 Reverse
<400> 12
gtccttcaat tccgacctgg 20
<210> 13
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Caspase9 Forward
<400> 13
gctgaaccgt gagcttttca 20
<210> 14
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Caspase9 Reverse
<400> 14
cctggcctgt gtcctctaag 20
<210> 15
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-BAX Forward
<400> 15
acttccttcg agatcggctg 20
<210> 16
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-BAX Reverse
<400> 16
aaagacacag tccaaggcgg 20
<210> 17
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-BCL2 Forward
<400> 17
gatgcctttg tggagctgta tg 22
<210> 18
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-BCL2 Reverse
<400> 18
cccgtggact tcacttatgg 20
<210> 19
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-PCNA Forward
<400> 19
tcgttgtgat tccaccacca t 21
<210> 20
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-PCNA Reverse
<400> 20
tgtcttcatt gccagcacat tt 22
<210> 21
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CDK1 Forward
<400> 21
aggtcaagtg gtagccatga a 21
<210> 22
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CDK1 Reverse
<400> 22
tccatgaact gaccaggagg 20
<210> 23
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CDK2 Forward
<400> 23
aaaagatcgg agagggcacg 20
<210> 24
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CDK2 Reverse
<400> 24
gcagtactgg gtacaccctc 20
<210> 25
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CDK4 Forward
<400> 25
cctcccggta tgaaccagtg 20
<210> 26
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CDK4 Reverse
<400> 26
tgctcaaaca ccagggtcac 20
<210> 27
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNA1 Forward
<400> 27
gcgccaaggc tggaatctat 20
<210> 28
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNA1 Reverse
<400> 28
cctcagtctc cacaggctac 20
<210> 29
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNA2 Forward
<400> 29
gtactgaagg ccgggaactc 20
<210> 30
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNA2 Reverse
<400> 30
agctggcctc ttttgagtct 20
<210> 31
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNB1 Forward
<400> 31
acggctgtta gctagtggtg 20
<210> 32
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNB1 Reverse
<400> 32
gagcagttct tggcctcagt 20
<210> 33
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNB2 Forward
<400> 33
tggaaatcga gttacaacca ga 22
<210> 34
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNB2 Reverse
<400> 34
tggagccaac atttccatct gt 22
<210> 35
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCND1 Forward
<400> 35
cttccatgcg gaagatcgtg 20
<210> 36
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCND1 Reverse
<400> 36
tggagttgtc ggtgtagatg c 21
<210> 37
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCND2 Forward
<400> 37
ttccccagtg ctcctacttc 20
<210> 38
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCND2 Reverse
<400> 38
cacaacttct cagccgtcag 20
<210> 39
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNE1 Forward
<400> 39
agcctgtgaa aacccctgtt 20
<210> 40
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNE1 Reverse
<400> 40
tccagaagaa tcgctcgcat 20
<210> 41
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNE2 Forward
<400> 41
gggggatcag tccttgcatt 20
<210> 42
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CCNE2 Reverse
<400> 42
agccaaacat cctgtgagca 20
<210> 43
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CYP19A1 Forward
<400> 43
ctgaagttgt gccttttgcc a 21
<210> 44
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CYP19A1 Reverse
<400> 44
ctgaggtagg aaattagggg c 21
<210> 45
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CYP11A1 Forward
<400> 45
tcccctctcc tggtgacaat 20
<210> 46
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-CYP11A1 Reverse
<400> 46
gccacatctt cagggtcgat 20
<210> 47
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-STAR Forward
<400> 47
cgacgtttaa gctgtgtgct 20
<210> 48
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-STAR Reverse
<400> 48
atccatgacc ctgaggttgg a 21
<210> 49
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-HSD17B1 Forward
<400> 49
gtctggcatc tgacccatct c 21
<210> 50
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-HSD17B1 Reverse
<400> 50
cgggcatccg ctattgaatc 20
<210> 51
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-HSD3B1 Forward
<400> 51
atctgcagga gatccgggta 20
<210> 52
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-HSD3B1 Reverse
<400> 52
ccttcatgac ggtctctcgc 20
<210> 53
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-GAPDH Forward
<400> 53
tcaccagggc tgcttttaac t 21
<210> 54
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-GAPDH Reverse
<400> 54
cttgactgtg ccgtggaact 20

Claims (11)

1.一种lncRNA IFFD,其特征在于:其核苷酸序列如SEQ ID NO:1所示。
2.权利要求1所述的lncRNA IFFD相关的生物材料,其特征在于:为下述生物材料中的任意一种;
1)编码所述lncRNA IFFD的DNA分子;
2)含有1)中所述DNA分子的表达盒;
3)含有1)中所述DNA分子的重组载体;
4)抑制所述lncRNA IFFD表达的siRNA;
所述siRNA如下所示:
si-lnc IFFD-1:5′-GCUCUAGCAGCUCGGACAA-3′;
5)含有1)中所述DNA分子的重组细胞,或转染有4)中所述siRNA的重组细胞;所述重组细胞为猪卵巢颗粒细胞。
3.根据权利要求2所述的生物材料,其特征在于:
3)中所述重组载体为含有2)中所述表达盒的重组载体;
5)中所述含有1)中所述DNA分子的重组细胞为含有2)中所述表达盒的重组细胞。
4.根据权利要求2所述的生物材料,其特征在于:
5)中所述含有1)中所述DNA分子的重组细胞为含有3)中所述重组载体的重组细胞。
5.根据权利要求2~4任一项所述的生物材料,其特征在于:
1)中所述DNA分子通过如下方式制备得到:提取猪卵巢颗粒细胞的RNA,将其逆转录成cDNA,以cDNA为模板进行PCR扩增,得到DNA分子;
PCR扩增所用引物如下所示:
lncRNA IFFD Forward:5′-CCAAGCTTTCTCTTGGGAAAGGAACAAAG-3′;
lncRNA IFFD Reverse:5′-GGGGTACCTCCCTACACCACCTTCCTGAC-3′。
6.根据权利要求2~4任一项所述的生物材料,其特征在于:
3)中所述重组载体通过如下方式制备得到:将所述DNA分子插入至pcDNA3.1载体的Hind III和Kpn I酶切位点之间,得到重组载体。
7.权利要求1所述的lncRNA IFFD或权利要求2~6任一项所述的生物材料在调控猪卵巢颗粒细胞增殖和/或凋亡中的应用,其特征在于:所述应用的环境为体外环境。
8.权利要求1所述的lncRNA IFFD或权利要求2~6任一项所述的生物材料在制备调控猪卵巢颗粒细胞增殖和/或凋亡的药物中的应用。
9.根据权利要求7或8所述的应用,其特征在于:为下述应用a)、b)、c)、d)中的任意一种,或者a)和b)的组合,或者c)和d)的组合:
a)增加lncRNA IFFD,抑制猪卵巢颗粒细胞的增殖;
b)增加lncRNA IFFD,促进猪卵巢颗粒细胞的凋亡;
c)减少lncRNA IFFD,促进猪卵巢颗粒细胞的增殖;
d)减少lncRNA IFFD,抑制猪卵巢颗粒细胞的凋亡。
10.权利要求1所述的lncRNA IFFD或权利要求2~6任一项所述的生物材料在制备调控猪卵巢颗粒细胞中E2生成的药物中的应用。
11.根据权利要求10所述的应用,其特征在于:
所述的调控猪卵巢颗粒细胞中E2生成通过如下方式实现:
增加lncRNA IFFD抑制E2的生成;或减少lncRNA IFFD促进E2的生成。
CN202210605258.9A 2022-05-31 2022-05-31 lncRNA IFFD及其在猪卵巢颗粒细胞中的应用 Active CN114836424B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210605258.9A CN114836424B (zh) 2022-05-31 2022-05-31 lncRNA IFFD及其在猪卵巢颗粒细胞中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210605258.9A CN114836424B (zh) 2022-05-31 2022-05-31 lncRNA IFFD及其在猪卵巢颗粒细胞中的应用

Publications (2)

Publication Number Publication Date
CN114836424A CN114836424A (zh) 2022-08-02
CN114836424B true CN114836424B (zh) 2023-08-29

Family

ID=82571884

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210605258.9A Active CN114836424B (zh) 2022-05-31 2022-05-31 lncRNA IFFD及其在猪卵巢颗粒细胞中的应用

Country Status (1)

Country Link
CN (1) CN114836424B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115992135A (zh) * 2022-08-30 2023-04-21 华南农业大学 LncRNA IFA及其在猪卵巢颗粒细胞中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111378663A (zh) * 2020-03-18 2020-07-07 吉林省农业科学院 lncRNA SFR1及其应用、调控卵泡发育的产品和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111378663A (zh) * 2020-03-18 2020-07-07 吉林省农业科学院 lncRNA SFR1及其应用、调控卵泡发育的产品和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Long non-coding RNAs in ovarian granulosa cells;Jiajie Tu等;Journal of Ovarian Research;第1-12页 *

Also Published As

Publication number Publication date
CN114836424A (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
Chen et al. RETRACTED: LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells
CN106995858B (zh) 一种与肝癌诊疗相关的lncRNA
CN114854756B (zh) miR-370调控GLI1表达在猪卵巢颗粒细胞中的应用
CN110384800B (zh) LncRNA XLOC_075168在制备促进血管新生的药物中的应用
Chen et al. Long noncoding RNA (lncRNA) FOXD2-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by regulating MiR-185/AKT axis
CN114836424B (zh) lncRNA IFFD及其在猪卵巢颗粒细胞中的应用
CN107663539A (zh) 环状RNA circ‑PTGR1的用途
CN114940992B (zh) lncRNA TAB2-AS调控TAB2在猪卵巢颗粒细胞中的应用
CN108559750B (zh) Stat3在猪卵巢颗粒细胞中的应用
CN111849866B (zh) H3K27me3调控FoxO1基因表达在猪卵巢颗粒细胞中的应用
CN107586850B (zh) 非编码基因在肝癌诊疗中的应用
CN107267616B (zh) 一种非编码基因生物标记物在肝癌中的应用
CN113388614B (zh) Rspo2基因在猪卵巢颗粒细胞中的应用
CN109852680B (zh) Fgfr1基因在猪卵巢颗粒细胞中的应用
CN107227362B (zh) 一种与肝癌相关的基因及其应用
CN117866956A (zh) LncRNA SFFD及其在猪卵巢颗粒细胞中的应用
CN110106182B (zh) p65基因在猪卵巢颗粒细胞中的应用
CN114934051A (zh) LncRNA TAB2-AS及其在猪卵巢颗粒细胞中的应用
CN106102772A (zh) 用于预防和/或治疗与dennd1a变体2相关疾病的组合物和方法
CN114875029B (zh) 一种调控猪卵巢颗粒细胞中lncRNA IFFD转录表达的方法
CN110577952B (zh) 干扰长非编码RNA的siRNA在制备治疗乳腺癌药物中的应用
CN107881237B (zh) 肺癌诊断标记物microRNA-4317及在药物和诊断试剂盒中的应用
CN114874993B (zh) 一种调控猪卵巢颗粒细胞mmp2基因表达的方法
CN107937523B (zh) 肺癌诊断标记物microRNA-3607-3p及在药物和诊断试剂盒中的应用
CN111471682A (zh) miR-23a作为诊断和治疗胃癌伪管生成标志物的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant